Amedisys Inc

Amedisys — Q1 2016 Earnings Presentation

16 slides from Amedisys's earnings presentation, May 3, 2016

  1. Slide 1: Amedisys Earnings Call Supplemental Materials

    Amedisys Earnings Call Supplemental Materials May 4, 2016 Exhibit 99.2

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and u

  3. Slide 3: Highlights and Summary Financial Results (Adjusted) – 1Q 2016

    Highlights and Summary Financial Results (Adjusted) – 1Q 2016 (1) Amedisys Consolidated Revenue Growth: +16% EBITDA: $24M EBITDA Margin: 6.9% EPS: $0.33 Amedisys Highlights SS Medicare Admissions: +4% SS Non-Medicare Admissions: +10% Medicare recert rate (2): 37% Cost per visit: +1% Home Health Outs

  4. Slide 4: Home Health and Hospice Segment (Adjusted) – 1Q 2016

    Home Health and Hospice Segment (Adjusted) – 1Q 2016 (1) Organic growth continuing in Medicare admissions; revenue mix improving (76% Medicare) +2% vs 4Q 2015 Non-Medicare continues to decline – 24% of revenue in 1Q 2016 vs 26% of revenue in 4Q 2015 *Recert rate drop due in large part to Infinity in

  5. Slide 5: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,4) Highlights G&A in business segments as a percentage of revenue relatively constant over the time period Corporate G&A cost increases driven by increase in outsourced services and HCHB maintenance costs that will be reduced and allocated out to the s

  6. Slide 6: Amedisys Strategy: Four Areas of Focus

    Amedisys Strategy: Four Areas of Focus Updated 1Q 2016 Clinicians Patient Health Clinicians Patient Health Clinical Distinction Employer of Choice Operational Excellence and Efficiency Driving Growth Outstanding Outcomes for Our Patients In Their Homes Amedisys Care Centers & Clinical Teams Current:

  7. Slide 7: Amedisys 1Q 2016 Report Card

    Amedisys 1Q 2016 Report Card Category Grade Comments Growth Strong organic volume growth quarter by quarter in home health and hospice. Quality Good progress on STARS and VBP. Analytics in place to drive numbers real time, moving clinical organization to regions to better problem solve. Hospice qual

  8. Slide 8: Driving Growth: Organic and Inorganic Opportunities

    Driving Growth: Organic and Inorganic 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes Inorganic Growth Opportunities Representing ~$75M in EBITDA * Includes 3,792 completed episodes from Infinity 10% Growth 21% Growth

  9. Slide 9: Operational Excellence: HCHB Implementation Timeline

    Operational Excellence: HCHB Implementation Timeline We have accelerated our HCHB implementation timeline with a target completion date of November 1, 2016, seven months ahead of our original plan. We are currently at 225 Installs including Infinity. Care Centers 210 Amedisys Installs and 15 Infinit

  10. Slide 10: Operational Excellence: Roadmap to EBITDA Improvement

    Operational Excellence: Roadmap to EBITDA Improvement IT and HCHB Efficiencies and Disruption ~$12M in savings by 4Q 17 Annualized impact ~$46M

  11. Slide 11: Becoming Employer of Choice: Improving Return on Human Capital

    Becoming Employer of Choice: Improving Return on Human Capital Total Voluntary Turnover up slightly from 2015 due to enterprise wide focus on terming inactive PRNs 593 PRNs termed in 1Q 2016 of which 221 were inactive / unproductive 1Q 2016Total Voluntary Turnover without unproductive PRN turnover ~

  12. Slide 12: Clinical Distinction: STARs and Value Based Purchasing

    Clinical Distinction: STARs and Value Based Purchasing Metric Release Amedisys Average* Industry Average Quality of Patient Care April 2016 3.50 3.25 Patient Survey April 2016 3.90 3.64 Quality of Patient Care and Patient Survey Results Value Based Purchasing Entities at 4+ Stars: 32% Internal goal

  13. Slide 13: Debt and Liquidity Metrics

    Debt and Liquidity Metrics As of: Outstanding Debt 03/31/16} Term Loan 98.8 i 16.0 Tota Debt Outstanding 113.8 Less: Deferred Finance a (3.2) Total Debt - Balance Sheet 110.6 Total Debt Outstanding 1138 Less: Cash (78) Net Debt 106.0 Leverage Ratio (net) © 1.0x As of: '$300M Credit Facility 03/31/16

  14. Slide 14: Adjusted EBITDA to Free Cash Flow Reconciliation

    Adjusted EBITDA to Free Cash Flow Reconciliation (1,3)

  15. Slide 15: Income Statement Adjustments

    Income Statement Adjustments (1)

  16. Slide 16: Endnotes

    Endnotes The financial results for the three-month periods ended March 31, 2015, June 30, 2015, September 30, 2015, December 31, 2015 and March 31, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is incl

Amedisys — Q1 2016 Earnings Presentation on 6ix